NON-SMALL CELL LUNG CANCER METASTATIC

This study compares a new experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive either the new drug o…

This study looks at whether a blood test (liquid biopsy) can help doctors monitor advanced lung cancer treatment better. 350 patients with non-small cell lung cancer that has spread will be enrolled. The goal is to see if this approach reduces unnecessary treatments and side effe…

This study tests a combination of two targeted drugs, lazertinib and tepotinib, in people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer) that has stopped responding to lazertinib alone due to a change in the MET gene. About 47 participants w…

This study is for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Researchers want to see if a blood test that measures tumor DNA (ctDNA) can help decide whether to add chemotherapy to the immunotherapy drug cemiplimab. About 63 participants w…

This study tests whether adding a precise, high-dose radiation treatment to the liver (called L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either stand…

This early-stage trial tests a treatment called GC101 TIL for people with advanced non-small cell lung cancer that has spread or come back. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the body to fight the cancer. The study w…

This study is for people with a type of lung cancer (NSCLC) that has spread to the brain. It compares taking a targeted pill (osimertinib) alone versus adding a precise form of radiation (SRS) after three months of the pill. The goal is to see which approach better delays brain t…

This study tests whether using a protein-based test to choose treatment can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard therapy …

This study tests a new antibody drug, OM-RCA-01, in people with advanced cancers that have a specific protein called FGFR1. The goal is to see if the drug is safe and can slow tumor growth. About 58 adults with kidney, lung, prostate, breast, or head & neck cancer will receive th…

This study is collecting information from 300 people in Italy with advanced non-small cell lung cancer who are receiving a treatment that combines two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy. The goal is to see how well this treatment works in everyday me…

This study watches 100 adults with a certain type of advanced lung cancer who are already receiving a drug combo (amivantamab plus chemo) through an early access program. Researchers want to see how long the treatment keeps the cancer from growing in everyday medical practice. No…